Business
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis...
About this update from Alumis Inc.
[{"type":"image","alt":"Alumis Inc.","displaySize":"","headline":null,"caption":"Alumis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D1V_aGoKejvy_01T3BfhbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911","width":150,"height":39}},"lazy":false},{"type":"text","content":"– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis –","length":151,"tagName":"p"},{"type":"text","content":"– Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average –","length":109,"tagName":"p"},{"type":"text","content":"– Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program –","length":111,"tagName":"p"},{"type":"text","content":"– Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 –","length":87,"tagName":"p"},{"type":"text","content":"– Conference call and webcast scheduled for 8:00 a.m. ET today –","length":64,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.","length":462,"tagName":"p"},{"type":"text","content":"Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2. In each of these trials, envudeucitinib achieved superior skin clearance compared with placebo (p < 0.0001) on the co‑primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0/1 at Week 16. On average across both ONWARD1 and ONWARD2, 74% of patients achieved PASI 75 and 59% of patients achieved sPGA 0/1, with responses deepening over time. In addition, the placebo...